Catalyst Wire Dossier Catalyst Wire Dossier

Granisetron transdermal system

Granisetron · Hisamitsu Pharmaceutical Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Granisetron transdermal system, covering 2017-11-17 to 2017-11-17. Get the full timeline:

Most recent: Clinical Trial Update: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy [Phase 1]

See pricing